RxDoctor Payments Data

Avani Kanneganti, MD

Internal Medicine · Dunkirk, NYNPI 1235585407

Payments from drug & device makers

$7,071in general payments, 2019–2025

Across 343 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$878
  • Novo Nordisk$653
  • Amgen$521
  • Boehringer Ingelheim$355
  • Exact Sciences$352
  • AbbVie$325
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$7,071100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,071 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$52,791
Medicare patients
167
Services billed
581

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide144$171,890
TrulicityDulaglutide114$136,508
EliquisApixaban108$124,203
JardianceEmpagliflozin111$116,159
RybelsusSemaglutide55$84,226
MounjaroTirzepatide49$53,975
FarxigaDapagliflozin Propanediol35$29,248
XareltoRivaroxaban23$28,496
JanuviaSitagliptin Phosphate14$20,482
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog61$18,733
Synjardy XrEmpagliflozin/Metformin Hcl11$18,652
VascepaIcosapent Ethyl15$13,732
MyrbetriqMirabegron14$12,713
Atorvastatin Calcium562$8,670
Icosapent Ethyl36$7,992

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$653$256,116199 claims
Lilly USA, LLCTrulicity, Mounjaro$323$190,483163 claims
Boehringer IngelheimJardiance, Synjardy Xr$355$134,810122 claims
PfizerEliquis, Paxlovid$239$127,028120 claims
AstraZenecaFarxiga, Symbicort$878$34,86449 claims
Johnson & JohnsonXarelto$87$28,49623 claims
MerckJanuvia$172$20,48214 claims
GSKTrelegy Ellipta, Breo Ellipta$238$15,35922 claims
Astellas Pharma US IncMyrbetriq$146$12,71314 claims
AbbVieSynthroid$325$4,63679 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Dunkirk

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →